<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alexander, Lori</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Valgimigli, Marco</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">3-Year Clinical Data Continue to Show Superiority of Sirolimus-Eluting versus Bare Metal Stents in STEMI Patients</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2007-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">10-11</style></pages><abstract><style  face="normal" font="default" size="100%">Results of 3 years of clinical follow-up data continued to show superiority for a combination of tirofiban+sirolimus-eluting stent (SES) vs a combination of abciximab+bare-metal stent (BMS) in STEMI patients, as evidenced by significantly reduced target vessel revascularization (TVR) rates.</style></abstract><number><style face="normal" font="default" size="100%">5</style></number><volume><style face="normal" font="default" size="100%">7</style></volume></record></records></xml>